Compound or practice · Supplement

Pycnogenol (Pine Bark)

A pine-bark polyphenol with broad small-trial signals for circulation, blood pressure, and skin — much of it single-source.

Overall grade
Grade C
Last revised
3
graded outcomes
0
references listed

A structured monograph in Prometheus's bundled library. Its grades are the monograph's own reading of the evidence, not a peer-reviewed review.

3 at grade C — 3 graded rows

What is known

Each outcome with its grade (how strong the evidence is, A to D), the size of the effect where the entry records one, and how often studies agree.

  • Venous insufficiencyEvidence grade C

    Symptom relief

    Smallmixed

  • Blood pressureEvidence grade C

    Modest

    Smallmixed

  • Skin elasticity/UVEvidence grade C

    Small trials

    Smallmixed

What is uncertain

Read off the same rows as above. Nothing here is added that the entry does not itself record.

  • Thin evidence: Venous insufficiency (grade C); Blood pressure (grade C); Skin elasticity/UV (grade C).
  • Caution with Blood-pressure medications: Additive blood-pressure lowering.

Interactions

Documented pairings with supplements and medicines. A medicine on this list is a conversation for whoever prescribes it.

  • Blood-pressure medicationsCaution

    Additive blood-pressure lowering.

The evidence in words

What it is

Pycnogenol is a standardized French maritime pine-bark extract rich in procyanidins.

How it works

Antioxidant and nitric-oxide-supporting actions improving microcirculation and endothelial function.

What the evidence shows

Many small trials suggest benefits for venous insufficiency, blood pressure, erectile function, and skin, but a large share come from the ingredient's maker, warranting caution. Mechanistically reasonable, independently thinner.

How to use it

100–200 mg/day standardized.

Safety & interactions

Generally safe; mild antiplatelet action; additive blood-pressure lowering. antihypertensives — Additive blood-pressure lowering.

Bottom line

Broad but largely single-source evidence for circulation and skin. Plausible and low-risk; weigh the industry-funding caveat.

How it is used

As the entry records it, from the studies it summarises. Not a recommendation for you — doses that suit a trial population may not suit you.

Standard
100–200 mg/day standardized.

Entries that share this one's tags or conditions.

Sources

This entry lists no references of its own.

Last revised . A grade is this entry's reading of the evidence, not medical advice.